AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26398070 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclavian vein catheterization
Number of subjects: 3027
Study 26398070 — intervention group
Group type: EXPERIMENTAL
Intervention: Jugular vein catheterization
Number of subjects: 3027
Study 26398070 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral vein catheterization
Number of subjects: 3027
Study 24955613 — intervention group
Group type: EXPERIMENTAL
Intervention: RB+PS (pigmented rice bran with plant sterols)
Number of subjects: 24
Study 24955613 — intervention group
Group type: COMPARATOR
Intervention: RB (pigmented rice bran)
Number of subjects: 24
Study 24955613 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 22958974 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol phenylbutyrate (1.5 to 31.8 g/day)
Number of subjects: 65
Study 22958974 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate (1.3 to 31.7 g/day)
Number of subjects: 65
Study 22958974 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma phenylacetylglutamine AUC(24-hour)
Number of subjects: 65
Study 22958974 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma phenylacetic acid AUC(24-hour)
Number of subjects: 65
Study 22958974 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutyric acid AUC(24-hour)
Number of subjects: 65
Study 19938965 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution chest computerized tomography (CT)
Number of subjects: 40
Study 19938965 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake (averaged over four days using 24-hour recalls)
Number of subjects: 40
Study 19938965 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function tests (percent predicted FEV(1))
Number of subjects: 40
Study 19938965 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression model of BMI, degree of emphysema, and calorie per kilogram body weight
Number of subjects: 40
Study 17523342 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (OPZ) 20 mg/day + AMPC 1500 mg/day + CAM 600 mg/day (OAC)
Number of subjects: 135
Study 17523342 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (LPZ) 30 mg + AMPC 1500 mg/day + CAM 600 mg/day (LAC)
Number of subjects: 135
Study 17523342 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (RPZ) 10 mg/day + AMPC 1500 mg/day + CAM 600 mg/day (RAC)
Number of subjects: 135
Study 17523342 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 phenotype - Homozygous extensive metabolizer (EM)
Number of subjects: 135
Study 17523342 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 phenotype - Heterozygous EM
Number of subjects: 135
Study 17523342 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 phenotype - Poor metabolizer
Number of subjects: 135
Study 15693450 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week of triple therapy (omeprazole 20 mg, clarithromycin 250 mg, tinidazole 500 mg)
Number of subjects: 82
Study 15693450 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks of triple therapy (omeprazole 20 mg, clarithromycin 250 mg, tinidazole 500 mg)
Number of subjects: 82
Study 15693450 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week of triple therapy
Number of subjects: 82
Study 15693450 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks of triple therapy
Number of subjects: 82
Study 11444994 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic waveform
Number of subjects: 30
Study 11444994 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic waveform
Number of subjects: 30
Study 11444994 — intervention group
Group type: COMPARATOR
Intervention: Polyphasic waveform
Number of subjects: 30
Study 11444994 — intervention group
Group type: EXPERIMENTAL
Intervention: All tested waveforms
Number of subjects: 30
Study 9918641 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mil superelastic Ni‐Ti archwires
Number of subjects: 155
Study 9918641 — intervention group
Group type: COMPARATOR
Intervention: 17.5 mil triple‐stranded steel archwires
Number of subjects: 155
Study 9918641 — intervention group
Group type: EXPERIMENTAL
Intervention: ion-implanted Ni-Ti archwires
Number of subjects: 155
Study 8050850 — intervention group
Group type: EXPERIMENTAL
Intervention: Short commands
Number of subjects: 0
Study 8050850 — intervention group
Group type: EXPERIMENTAL
Intervention: Short affective vignettes with tag lines
Number of subjects: 0
Study 8050850 — intervention group
Group type: EXPERIMENTAL
Intervention: Short affective vignettes without tag lines
Number of subjects: 0
Study 8050850 — intervention group
Group type: EXPERIMENTAL
Intervention: Long affective vignettes with tag lines
Number of subjects: 0
Study 8050850 — intervention group
Group type: EXPERIMENTAL
Intervention: Long affective vignettes without tag lines
Number of subjects: 0
Study 8050850 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignettes presented
Number of subjects: 0
Study 1901638 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot, 3.75 mg intramuscularly every 4 weeks for 24 weeks
Number of subjects: 128
Study 1901638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 1901638 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot
Number of subjects: 128
Study 354098 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 125
Study 354098 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 125
Study 31817936 — intervention group
Group type: EXPERIMENTAL
Intervention: Zumba Fitness® (ZF)
Number of subjects: 98
Study 31817936 — intervention group
Group type: EXPERIMENTAL
Intervention: Zumba Fitness with Bodyweight strength training (ZF + BW)
Number of subjects: 98
Study 31817936 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 98
Study 28698987 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-set (TRI) resistance training
Number of subjects: 14
Study 28698987 — intervention group
Group type: EXPERIMENTAL
Intervention: Superset (SS) resistance training
Number of subjects: 14
Study 28698987 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional (TRAD) resistance training
Number of subjects: 14
Study 25847559 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg/kg Ginkgo biloba extract (G group n=30)
Number of subjects: 60
Study 25847559 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (D group n=30)
Number of subjects: 60
Study 22833264 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) view consisting of an endoscopic video fused with anatomic contours
Number of subjects: 32
Study 22833264 — intervention group
Group type: COMPARATOR
Intervention: Standard endoscopic view (control)
Number of subjects: 32
Study 20929947 — intervention group
Group type: EXPERIMENTAL
Intervention: TYL intervention (Transforming Your Life)
Number of subjects: 54
Study 20929947 — intervention group
Group type: COMPARATOR
Intervention: LEARN intervention (traditional behavioral weight loss program)
Number of subjects: 54
Study 20929947 — intervention group
Group type: EXPERIMENTAL
Intervention: TYL intervention
Number of subjects: 54
Study 20929947 — intervention group
Group type: COMPARATOR
Intervention: LEARN intervention
Number of subjects: 54
Study 19438787 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 84
Study 19438787 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 84
Study 19438787 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air
Number of subjects: 84
Study 19438787 — intervention group
Group type: EXPERIMENTAL
Intervention: Air and papaverine
Number of subjects: 84
Study 17062048 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 30
Study 17062048 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 30
Study 16166876 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfect health version
Number of subjects: 1015
Study 16166876 — intervention group
Group type: EXPERIMENTAL
Intervention: Your-age version
Number of subjects: 1015
Study 16166876 — intervention group
Group type: COMPARATOR
Intervention: 20-year-old version
Number of subjects: 1015
Study 12665408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization with movement for the elbow
Number of subjects: 24
Study 12665408 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 24
Study 10416459 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance training for 18 months
Number of subjects: 93
Study 10416459 — intervention group
Group type: COMPARATOR
Intervention: Dropout group (control)
Number of subjects: 93
Study 7559260 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaditen SRO 4 mg once daily
Number of subjects: 362
Study 7559260 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaditen SRO 2 mg once daily
Number of subjects: 362
Study 7559260 — intervention group
Group type: COMPARATOR
Intervention: Zaditen Standard Form 1 mg twice daily
Number of subjects: 362
Study 2196774 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous captopril (n = 8)
Number of subjects: 12
Study 2196774 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 4)
Number of subjects: 12
Study 7025625 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg/day
Number of subjects: 16
Study 7025625 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg/day
Number of subjects: 16
Study 7025625 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 240 mg/day
Number of subjects: 16
Study 7025625 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 280 mg/day
Number of subjects: 16
Study 7025625 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Nifedipine and Propranolol
Number of subjects: 16
Study 7025625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12445036 — intervention group
Group type: EXPERIMENTAL
Intervention: NewRinsed spacer
Number of subjects: 25
Study 12445036 — intervention group
Group type: COMPARATOR
Intervention: Primed1 spacer
Number of subjects: 25
Study 12445036 — intervention group
Group type: COMPARATOR
Intervention: Used spacer
Number of subjects: 25
Study 31924277 — intervention group
Group type: EXPERIMENTAL
Intervention: Medrave 4 program for data extraction
Number of subjects: 86
Study 29199100 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal antiretroviral therapy (ART) with fixed-dose combination of tenofovir, emtricitabine, and efavirenz, regardless of CD4 cell count.
Number of subjects: 26518
Study 29199100 — intervention group
Group type: COMPARATOR
Intervention: Control group followed national guidelines for ART initiation (initially ≤350 cells per μL and <500 cells per μL from January 2015).
Number of subjects: 26518
Study 29199100 — intervention group
Group type: COMPARATOR
Intervention: Both intervention and control groups.
Number of subjects: 26518
Study 27585969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg every 8 h
Number of subjects: 761
Study 27585969 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (15 mg/kg every 12 h) plus aztreonam (1 g every 8 h)
Number of subjects: 761
Study 27585969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg every 8 h and Vancomycin plus aztreonam
Number of subjects: 761
Study 24395288 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and cholecalciferol supplementation (1,000 mg/day calcium and 800 IU cholecalciferol)
Number of subjects: 275
Study 24395288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 24395288 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling with supplementation
Number of subjects: 275
Study 26856037 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 minute alarm reminder system
Number of subjects: 127
Study 26856037 — intervention group
Group type: COMPARATOR
Intervention: Non-alarm control
Number of subjects: 127
Study 20332588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 25 mg
Number of subjects: 363
Study 20332588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg
Number of subjects: 363
Study 20332588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 363
Study 20332588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 200 mg
Number of subjects: 363
Study 20332588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (all doses)
Number of subjects: 363
Study 20332588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 18618189 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement plus brief telephone coaching (QI-plus)
Number of subjects: 719
Study 18618189 — intervention group
Group type: COMPARATOR
Intervention: Quality Improvement only (QI-only)
Number of subjects: 719
Study 16284747 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg daily)
Number of subjects: 2838
Study 16284747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2838
Study 12392456 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance respirometry
Number of subjects: 79
Study 9915432 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy
Number of subjects: 147
Study 9915432 — intervention group
Group type: COMPARATOR
Intervention: Transurethral prostatic resection
Number of subjects: 147
Study 7751881 — intervention group
Group type: EXPERIMENTAL
Intervention: modified LSA2L2
Number of subjects: 281
Study 7751881 — intervention group
Group type: COMPARATOR
Intervention: ADCOMP (which included daunorubicin and asparaginase)
Number of subjects: 281
Study 7751881 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 281
Study 2267964 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily)
Number of subjects: 253
Study 2267964 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine (250 mg weekly)
Number of subjects: 253
Study 7403543 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT) before Radionuclide Scanning (RN)
Number of subjects: 1643
Study 7403543 — intervention group
Group type: COMPARATOR
Intervention: Radionuclide Scanning (RN) before Computed Tomography (CT)
Number of subjects: 1643
Study 30892987 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib 300 mg daily, binimetinib 45 mg twice daily, plus standard weekly cetuximab
Number of subjects: 30
Study 28759172 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin-induced labor
Number of subjects: 64
Study 28759172 — intervention group
Group type: COMPARATOR
Intervention: No labor induction (Control)
Number of subjects: 64
Study 26219161 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 64
Study 26219161 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia combined with Continuous Epidural Anesthesia (GCEA)
Number of subjects: 64
Study 23512648 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (8 weeks)
Number of subjects: 26
Study 23512648 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 21812889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 279
Study 21812889 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg
Number of subjects: 279
Study 21812889 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 or 40 mg
Number of subjects: 279
Study 21812889 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 279
Study 21812889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 279
Study 19624299 — intervention group
Group type: COMPARATOR
Intervention: CRT5 (five-field conformal radiotherapy)
Number of subjects: 18
Study 19624299 — intervention group
Group type: COMPARATOR
Intervention: IMRT(for) (forward-planned intensity-modulated radiotherapy)
Number of subjects: 18
Study 19624299 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT(inv) (inverse-planned multi-segment solution)
Number of subjects: 18
Study 16449339 — intervention group
Group type: EXPERIMENTAL
Intervention: sc PTH (1-84), 100 mug/d
Number of subjects: 238
Study 15328551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 15
Study 15328551 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 15
Study 11035889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole, 0.5 mg 3 times per day, with levodopa placebo (n = 151)
Number of subjects: 301
Study 11035889 — intervention group
Group type: COMPARATOR
Intervention: Carbidopa/levodopa, 25/100 mg 3 times per day, with pramipexole placebo (n = 150)
Number of subjects: 301
Study 11035889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 301
Study 11035889 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 301
Study 11035889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (n = 39)
Number of subjects: 301
Study 11035889 — intervention group
Group type: COMPARATOR
Intervention: Levodopa (n = 39)
Number of subjects: 301
Study 8848410 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentrations of neuropeptide Y (NPY)
Number of subjects: 0
Study 8848410 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentrations of noradrenaline (NA)
Number of subjects: 0
Study 8848410 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentrations of endothelin‐1,2 (ET‐1,2)
Number of subjects: 0
Study 8848410 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentrations of alpha atrial natriuretic polypeptide (ANP)
Number of subjects: 0
Study 2062628 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (ACV) booster at 19 months
Number of subjects: 41
Study 6825123 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic nucleoside phosphate (iv infusion over 15 minutes once every 3 weeks, doses ranged from 25 to 350 mg/m2)
Number of subjects: 20
Study 31310929 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Depression Therapy (ADepT)
Number of subjects: 11
Study 27474364 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingualized occlusion (LO)
Number of subjects: 60
Study 27474364 — intervention group
Group type: COMPARATOR
Intervention: Fully bilateral balanced articulation (FBBA)
Number of subjects: 60
Study 26077241 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Number of subjects: 130
Study 26077241 — intervention group
Group type: COMPARATOR
Intervention: Comparator (progestin or investigator choice chemotherapy)
Number of subjects: 130
Study 23585665 — intervention group
Group type: EXPERIMENTAL
Intervention: canagliflozin 100 mg/d for 8 days
Number of subjects: 28
Study 23585665 — intervention group
Group type: COMPARATOR
Intervention: No treatment intervention
Number of subjects: 28
Study 22226269 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoTwist insulin pen needle
Number of subjects: 30
Study 19358940 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 3429
Study 16423633 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein, low-carbohydrate diet (20:30:50 carbohydrate-protein-fat ratio)
Number of subjects: 0
Study 16423633 — intervention group
Group type: COMPARATOR
Intervention: Control diet (55:15:30 carbohydrate-protein-fat ratio)
Number of subjects: 0
Study 15265190 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 33
Study 11412156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (20 mg.4 h‐1)
Number of subjects: 120
Study 11412156 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol (2 g.6 h‐1)
Number of subjects: 120
Study 11412156 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone (Control)
Number of subjects: 120
Study 11412156 — intervention group
Group type: COMPARATOR
Intervention: Control group (Morphine alone)
Number of subjects: 120
Study 11412156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam group
Number of subjects: 120
Study 11412156 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol group
Number of subjects: 120
Study 9524832 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1,200 mg once weekly)
Number of subjects: 174
Study 9524832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 8014323 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 66
Study 8014323 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 66
Study 8014323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 2512804 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalline zinc insulin (CZI) in each liter of TPN solution
Number of subjects: 0
Study 2512804 — intervention group
Group type: COMPARATOR
Intervention: No additional insulin (control group)
Number of subjects: 0
Study 5031712 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 6
Study 5031712 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 6
Study 30479538 — intervention group
Group type: COMPARATOR
Intervention: 1 minute stair climbing
Number of subjects: 30
Study 30479538 — intervention group
Group type: COMPARATOR
Intervention: 3 minutes stair climbing
Number of subjects: 30
Study 30479538 — intervention group
Group type: COMPARATOR
Intervention: 10 minutes stair climbing
Number of subjects: 30
Study 31590681 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet Cognitive Therapy
Number of subjects: 40
Study 31590681 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 40
Study 27897186 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage Therapy (MT) - Swedish massage to upper body
Number of subjects: 40
Study 27897186 — intervention group
Group type: COMPARATOR
Intervention: Guided Imagery (GI) relaxation
Number of subjects: 40
Study 25500799 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 548
Study 25500799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 548
Study 23884387 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot bread (BB) - 200 g containing 100 g beetroot (1.1 mmol nitrate)
Number of subjects: 23
Study 23884387 — intervention group
Group type: COMPARATOR
Intervention: Control white bread (CB) - 200 g (0 g beetroot, 0.01 mmol nitrate)
Number of subjects: 23